{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:14:24Z","timestamp":1791422064171,"version":"4.3.3"},"reference-count":63,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma is a plasma cell cancer with poor survival, characterized by the clonal expansion of multiple myeloma cells (MMC), primarily in the bone marrow. Novel compounds are currently tested in this disease, but partial or minor patients' responses are observed for most compounds used as a single agent. The design of predictors for drug efficacy could be most useful to better understand basic mechanisms targeted by these drugs and design clinical trials. In the current study, we report the building of a DNA methylation score (DM score) predicting the efficacy of decitabine, an inhibitor of DNA methyltransferase (DNMT), targeting methylation-regulated gene expression. DM score was built by identifying 47 genes regulated by decitabine in human myeloma cell lines and the expression of which in primary MMCs of previously untreated patients is predictive for overall survival. A high DM score predicts patients' poor survival, and, of major interest, high sensitivity of primary MMCs or human myeloma cell lines to decitabine in vitro. Thus, DM score could be useful to design novel treatments with DMNT inhibitor in multiple myeloma and has highlighted 47 genes, the gene products of which could be important for multiple myeloma disease development. Mol Cancer Ther; 11(12); 2685\u201392. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/1535-7163.mct-12-0721","type":"journal-article","created":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T21:32:36Z","timestamp":1350682356000},"page":"2685-2692","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Development of Gene Expression\u2013Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors"],"prefix":"10.1158","volume":"11","author":[{"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"},{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"R\u00e8me","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"},{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Leonard","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Veyrune","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"},{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Requirand","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"},{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"},{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"},{"name":"Authors' Affiliations:\u20081CHU Montpellier, Institute of Research in Biotherapy; 2INSERM, U1040, Montpellier; 3Universit\u00e9 MONTPELLIER1, UFR M\u00e9decine, Montpellier, France; 4Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg; and 5Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2012,12,9]]},"reference":[{"key":"2022060800060035600_bib1","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJMra021902","article-title":"Rules for making human tumor cells","volume":"347","author":"Hahn","year":"2002","journal-title":"N Engl J Med"},{"key":"2022060800060035600_bib2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat Med"},{"key":"2022060800060035600_bib3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"2","author":"Baylin","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"2022060800060035600_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3349\/ymj.2009.50.4.455","article-title":"Epigenetic cross-talk between DNA methylation and histone modifications in human cancers","volume":"50","author":"Kondo","year":"2009","journal-title":"Yonsei Med J"},{"key":"2022060800060035600_bib5","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1158\/1078-0432.CCR-06-2076","article-title":"DNA methylation as a therapeutic target in cancer","volume":"13","author":"Issa","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022060800060035600_bib6","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"2022060800060035600_bib7","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1182\/blood-2007-07-103960","article-title":"Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia","volume":"111","author":"Oki","year":"2008","journal-title":"Blood"},{"key":"2022060800060035600_bib8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2141.2009.07976.x","article-title":"The potential role of epigenetic therapy in multiple myeloma","volume":"148","author":"Smith","year":"2010","journal-title":"Br J Haematol"},{"key":"2022060800060035600_bib9","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060800060035600_bib10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"2022060800060035600_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-0609.2008.01189.x","article-title":"Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma","volume":"82","author":"Chen","year":"2009","journal-title":"Eur J Haematol"},{"key":"2022060800060035600_bib12","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/ijc.24431","article-title":"TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma","volume":"125","author":"de Carvalho","year":"2009","journal-title":"Int J Cancer"},{"key":"2022060800060035600_bib13","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood-2002-06-1735","article-title":"SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma","volume":"101","author":"Galm","year":"2003","journal-title":"Blood"},{"key":"2022060800060035600_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3816\/CLM.2009.n.047","article-title":"Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease","volume":"9","author":"Hatzimichael","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"2022060800060035600_bib15","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-04-3589","article-title":"Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation","volume":"65","author":"Hodge","year":"2005","journal-title":"Cancer Res"},{"key":"2022060800060035600_bib16","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood.V89.7.2500","article-title":"Frequent hypermethylation of p16 and p15 genes in multiple myeloma","volume":"89","author":"Ng","year":"1997","journal-title":"Blood"},{"key":"2022060800060035600_bib17","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/cncr.20295","article-title":"DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies","volume":"100","author":"Seidl","year":"2004","journal-title":"Cancer"},{"key":"2022060800060035600_bib18","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.exphem.2008.08.001","article-title":"Epigenetic silencing of the interferon regulatory factor ICSBP\/IRF8 in human multiple myeloma","volume":"36","author":"Tshuikina","year":"2008","journal-title":"Exp Hematol"},{"key":"2022060800060035600_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/0008-5472.CAN-07-2531","article-title":"Genome-wide transcriptional response to 5-aza-2\u2032-deoxycytidine and trichostatin a in multiple myeloma cells","volume":"68","author":"Heller","year":"2008","journal-title":"Cancer Res"},{"key":"2022060800060035600_bib20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4161\/epi.6.8.16167","article-title":"Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma","volume":"6","author":"Wilop","year":"2011","journal-title":"Epigenetics"},{"key":"2022060800060035600_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"2022060800060035600_bib22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.2010.033456","article-title":"A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines","volume":"96","author":"Moreaux","year":"2011","journal-title":"Haematologica"},{"key":"2022060800060035600_bib23","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","article-title":"Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma","volume":"83","author":"Zhang","year":"1994","journal-title":"Blood"},{"key":"2022060800060035600_bib24","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/blood.V91.12.4727","article-title":"A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma","volume":"91","author":"Rebouissou","year":"1998","journal-title":"Blood"},{"key":"2022060800060035600_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4049\/jimmunol.163.1.514","article-title":"Induced expression of B7\u20131 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells","volume":"163","author":"Tarte","year":"1999","journal-title":"J Immunol"},{"key":"2022060800060035600_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/sj.leu.2401632","article-title":"Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors","volume":"14","author":"Gu","year":"2000","journal-title":"Leukemia"},{"key":"2022060800060035600_bib27","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00277-003-0685-2","article-title":"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients","volume":"82","author":"Goldschmidt","year":"2003","journal-title":"Ann Hematol"},{"key":"2022060800060035600_bib28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/gcc.20231","article-title":"Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics","volume":"44","author":"Cremer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"2022060800060035600_bib29","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"2022060800060035600_bib30","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2008-07-170464","article-title":"The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor","volume":"113","author":"Sprynski","year":"2009","journal-title":"Blood"},{"key":"2022060800060035600_bib31","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","article-title":"An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma","volume":"112","author":"Xiong","year":"2008","journal-title":"Blood"},{"key":"2022060800060035600_bib32","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2003-05-1510","article-title":"An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis","volume":"103","author":"Mahtouk","year":"2004","journal-title":"Blood"},{"key":"2022060800060035600_bib33","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","article-title":"Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma","volume":"113","author":"Hose","year":"2009","journal-title":"Blood"},{"key":"2022060800060035600_bib34","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"key":"2022060800060035600_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2105-9-16","article-title":"A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments","volume":"9","author":"Reme","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"2022060800060035600_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1875036201004010005","article-title":"Amazonia!: an online resource to Google and visualize public human whole genome expression data","volume":"4","author":"Le Carrour","year":"2010","journal-title":"Open Bioinformatics J"},{"key":"2022060800060035600_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/gb-2003-4-4-210","article-title":"Statistical tests for differential expression in cDNA microarray experiments","volume":"4","author":"Cui","year":"2003","journal-title":"Genome Biol"},{"key":"2022060800060035600_bib38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2011.046821","article-title":"Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma","volume":"97","author":"Kassambara","year":"2012","journal-title":"Haematologica"},{"key":"2022060800060035600_bib39","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2022060800060035600_bib40","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/leu.2009.160","article-title":"The molecular characterization and clinical management of multiple myeloma in the post-genome era","volume":"23","author":"Zhou","year":"2009","journal-title":"Leukemia"},{"key":"2022060800060035600_bib41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/jir.2010.0134","article-title":"Interferon-alpha induces reversible DNA demethylation of the interferon-induced transmembrane protein-3 core promoter in human melanoma cells","volume":"31","author":"Scott","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"2022060800060035600_bib42","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.4049\/jimmunol.161.6.2692","article-title":"IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis","volume":"161","author":"Ferlin-Bezombes","year":"1998","journal-title":"J Immunol"},{"key":"2022060800060035600_bib43","doi-asserted-by":"crossref","first-page":"11799","DOI":"10.1074\/jbc.273.19.11799","article-title":"Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression","volume":"273","author":"Arora","year":"1998","journal-title":"J Biol Chem"},{"key":"2022060800060035600_bib44","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy","volume":"322","author":"Mandelli","year":"1990","journal-title":"N Engl J Med"},{"key":"2022060800060035600_bib45","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022060800060035600_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","article-title":"A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results","volume":"102","author":"Cunningham","year":"1998","journal-title":"Br J Haematol"},{"key":"2022060800060035600_bib47","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"key":"2022060800060035600_bib48","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood-2010-05-284422","article-title":"Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival","volume":"117","author":"Steinbrunn","year":"2011","journal-title":"Blood"},{"key":"2022060800060035600_bib49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","article-title":"Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors","volume":"105","author":"Rasmussen","year":"2005","journal-title":"Blood"},{"key":"2022060800060035600_bib50","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","article-title":"Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial","volume":"88","author":"Liu","year":"1996","journal-title":"Blood"},{"key":"2022060800060035600_bib51","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrc2682","article-title":"RecQ helicases: multifunctional genome caretakers","volume":"9","author":"Chu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022060800060035600_bib52","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.biochi.2003.10.006","article-title":"Human diseases deficient in RecQ helicases","volume":"85","author":"Harrigan","year":"2003","journal-title":"Biochimie"},{"key":"2022060800060035600_bib53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc1012","article-title":"RecQ helicases: caretakers of the genome","volume":"3","author":"Hickson","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2022060800060035600_bib54","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-11-0320","article-title":"RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma","volume":"71","author":"Arai","year":"2011","journal-title":"Cancer Res"},{"key":"2022060800060035600_bib55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1349-7006.2007.00647.x","article-title":"Induction of mitotic cell death in cancer cells by small interference RNA suppressing the expression of RecQL1 helicase","volume":"99","author":"Futami","year":"2008","journal-title":"Cancer Sci"},{"key":"2022060800060035600_bib56","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1349-7006.2008.00794.x","article-title":"Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models","volume":"99","author":"Futami","year":"2008","journal-title":"Cancer Sci"},{"key":"2022060800060035600_bib57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1476-4598-10-83","article-title":"The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation","volume":"10","author":"Mendoza-Maldonado","year":"2011","journal-title":"Mol Cancer"},{"key":"2022060800060035600_bib58","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.tcb.2005.07.006","article-title":"Analysis of the kinesin superfamily: insights into structure and function","volume":"15","author":"Miki","year":"2005","journal-title":"Trends Cell Biol"},{"key":"2022060800060035600_bib59","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1126\/science.279.5350.519","article-title":"Kinesin and dynein superfamily proteins and the mechanism of organelle transport","volume":"279","author":"Hirokawa","year":"1998","journal-title":"Science"},{"key":"2022060800060035600_bib60","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1002\/cncr.25461","article-title":"The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy","volume":"116","author":"Yu","year":"2010","journal-title":"Cancer"},{"key":"2022060800060035600_bib61","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1091\/mbc.e05-02-0167","article-title":"Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis\/cytokinesis using RNA interference","volume":"16","author":"Zhu","year":"2005","journal-title":"Mol Biol Cell"},{"key":"2022060800060035600_bib62","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060800060035600_bib63","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1158\/1078-0432.CCR-11-0596","article-title":"The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma","volume":"17","author":"Agnelli","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/11\/12\/2685\/2320401\/2685.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/11\/12\/2685\/2320401\/2685.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:02:18Z","timestamp":1714467738000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/11\/12\/2685\/91204\/Development-of-Gene-Expression-Based-Score-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,1]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12,9]]},"published-print":{"date-parts":[[2012,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-12-0721","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1535-7163.22496610.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.c.6535332.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496604.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496601.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496619","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496607.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496616","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496604","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496607","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496601","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496622","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496625.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496625","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496622.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496613","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496610","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496613.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496616.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22496619.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.c.6535332","asserted-by":"object"}]},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,1]]}}}